Shares of the South San Francisco-based firm's stock (NASDAQ:CEGE) hit rock bottom on the news, tumbling 72 percent, or 44 cents, to close Thursday at a meager 17 cents. It's a record low for the company, which had traded close to the $3 mark in late August before falling 70 percent when its other Phase III study of GVAX was terminated due to an imbalance of deaths in the treatment arm. (BioWorld Today)